Fidaxomicin heterologous expression engineering strain and construction and application thereof
By introducing the ermEp* promoter into Streptomyces whiteus J1074 to modify the fenadamycin biosynthesis gene cluster and optimizing the culture medium, a highly efficient fenadamycin heterologous expression engineered strain was constructed, solving the problem of treating drug-resistant CDI and realizing the efficient production of fenadamycin.
Patent Information
- Application Number
- CN202410903881.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-05
- Publication Date
- 2024-11-01
AI Technical Summary
Existing technologies face the problem of increasing drug-resistant strains when treating Clostridium difficile infection (CDI), and there is a lack of efficient methods for producing fenamidac.
A heterologous expression strain of fenadimidine was constructed, using Streptomyces albopictus J1074 as the host strain. The fenadimidine biosynthesis gene cluster was modified by introducing the ermEp* promoter, and the production efficiency of fenadimidine was improved by optimizing the culture medium composition.
It has achieved efficient production of fenadine, shortened the fermentation cycle, improved production efficiency, and achieved a yield 7.6 times that of Deccan Plateau Actinomyces YP-1, which has broad industrial application value.
Smart Images

Figure CN118879593A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the field of pharmaceutical biotechnology, and in particular to an engineering Streptomyces strain for heterologously expressing fidaxomicin. Background Art
[0002] Clostridium difficile infection (CDI) is an infectious disease caused by the excessive reproduction and toxin release of Clostridium difficile, which has the risk of causing colitis, severe diarrhea and death. Historical data show that CDI is more common in the elderly, long-term hospitalized patients and patients in intensive care units, but recent reports of infections in healthy adults and children have also increased. Clostridium difficile is a Gram-positive bacillus. Currently, the first-choice drugs for the treatment of CDI include metronidazole and vancomycin, but with the increasing number of drug-resistant strains, there is an urgent need to develop more effective treatments.
[0003] Fidaxomicin is a new type of macrolide antibiotic that can be taken orally. The drug was approved for marketing by the US FDA in May 2011, but has not yet been approved by the CFDA in China. Clinical trials have shown that fidaxomicin is not only significantly superior to vancomycin in treatment, but can also effectively inhibit Clostridium difficile and effectively reduce the recurrence of infection caused by this bacteria. Summary of the invention
[0004] The purpose of the present invention is to provide a fidaxomicin heterologous expression engineered strain and its construction and application. The engineered strain can be obtained by simple transformation based on commercial biological materials, and can simplify the construction process of the engineered strain, improve the efficiency of the introduction of the target gene, and can also achieve rapid and efficient fidaxomicin production.
[0005] The technical solution adopted by the present invention is:
[0006] (I) Fidaxomicin heterologous expression engineering strain
[0007] The host bacteria of the engineering strain is Streptomyces albus J1074; the engineering strain expresses the modified fidaxomicin biosynthetic gene cluster.
[0008] Specifically, the modified fidaxomicin biosynthetic gene cluster is formed by replacing the promoter of the fidaxomicin biosynthetic gene cluster with the ermEp* promoter, the sequence of the ermEp* promoter is shown in SEQ ID NO.5, and the fidaxomicin biosynthetic gene cluster is derived from Actinoplanes deccanensis YP-1. The GenBank sequence accession number of the fidaxomicin biosynthetic gene cluster is MG972807.1, which can be obtained by commercial means by those skilled in the art.
[0009] Specifically, the modified fidaxomicin biosynthesis gene cluster comprises the fadP1 gene, the fadP1 promoter sequence, the ermEp* promoter sequence and the ampicillin resistance gene, the fadS5 gene and the fadR1 gene; the fadP1 gene is located upstream of the ermEp* promoter and the ampicillin resistance gene, the fadS5 gene is located downstream of the ermEp* promoter sequence, and the fadR1 gene is located downstream of the fadS5 gene. The fadP1 gene is located at bases 1 to 1179 of the base sequence shown in SEQ ID NO.12, and expresses cytochrome P450 hydroxylase protein; the fadP1 promoter sequence is located at bases 1180 to 1599 of the base sequence shown in SEQ ID NO.12, the ampicillin resistance gene sequence is located at bases 1600 to 2460 of the base sequence shown in SEQ ID NO.12, the ermEp* promoter sequence is located at bases 2461 to 2708 of the base sequence shown in SEQ ID NO.12, the fadS5 gene is located at bases 2709 to 4019 of the base sequence shown in SEQ ID NO.12, and expresses oxygen methyltransferase protein; the fadR1 gene is located at bases 4020 to 6825 of the base sequence shown in SEQ ID NO.12, and expresses pathway-specific regulatory protein.
[0010] Specifically, the engineering strain is classified and named Streptomyces albus Efad, the preservation unit is the General Microbiology Center of China Microbiological Culture Collection Administration, the preservation number is CGMCCNO.30730, and the preservation date is May 22, 2024.
[0011] (II) Construction of heterologous expression engineered strain of fidaxomicin
[0012] The method for constructing the heterologous expression engineering strain of Fidaxomicin comprises the following steps:
[0013] S1, using the fidaxomicin biosynthetic gene cluster as the target gene cluster, using two pairs of specific primers to screen the plasmid pMSBBAC1-fad containing the target gene cluster by mixed colony PCR method; wherein the two pairs of specific primers include a first specific primer pair and a second specific primer pair, the first specific primer pair consists of primer fad-F1 and primer fad-R1, the second specific primer pair consists of primer fadF2 and primer fadR2, and the nucleotide sequences of the primer fad-F1, primer fad-R1, primer fadF2, and primer fadR2 are shown in SEQ ID NO.1, SEQ ID NO.2, SEQ ID NO.3, and SEQ ID NO.4, respectively. Specifically comprising the following steps:
[0014] S1.1, taking the fidaxomicin biosynthetic gene cluster as the target gene cluster, and designing two pairs of specific primers based on the sequence of the target gene cluster;
[0015] S1.2, using two pairs of specific primers to locate the target gene cluster from the BAC library of Deccan Plateau Actinomycetes YP-1, and using the mixed colony PCR method to screen and obtain Escherichia coli containing the target gene cluster;
[0016] S1.3, culturing the Escherichia coli containing the target gene cluster, and extracting a large plasmid from the Escherichia coli containing the target gene cluster to obtain a plasmid pMSBBAC1-fad containing the target gene cluster. The large plasmid specifically refers to a plasmid larger than 10 kb.
[0017] S2. constructing a fragment EPA by PCR technology, wherein the sequence of the fragment EPA includes the ermEp* promoter and the ampicillin resistance tag, and the sequence of the ampicillin resistance tag is shown in SEQ ID NO. 6. Specifically comprising the following steps:
[0018] S2.1, using primers ermEp*-F1 and primer ermEp*R1 to amplify the ermEp* promoter using pIJ8630-ermEp* as a template, and recovering the ermEp* promoter; at the same time, using primers AMP-F2 and primer AMP-R2 to amplify the ampicillin resistance tag using the pTA2 vector as a template, and recovering the ampicillin resistance tag;
[0019] S2.2, using primers ermEp*-F1 and primer AMP-R2 to perform fusion PCR with the ermEp* promoter and the ampicillin resistance tag as templates to obtain fragment EPA;
[0020] The nucleotide sequences of the primer ermEp*-F1, primer ermEp*R1, primer AMP-F2, and primer AMP-R2 are shown as SEQ ID NO.7, SEQ ID NO.8, SEQ ID NO.9, and SEQ ID NO.10, respectively; the nucleotide sequence of the fragment EPA is shown as SEQ ID NO.11.
[0021] S3, electroporating the mixture of the plasmid pMSBBAC1-fad containing the target gene cluster obtained in step S1, the fragment EPA obtained in step S2 and the competent E. coli GB05RedTrfA to obtain the plasmid pMSBBAC1-Efad containing the modified fidaxomicin biosynthetic gene cluster. Specifically comprising the following steps:
[0022] S3.1. Mix the plasmid pMSBBAC1-fad containing the target gene cluster obtained in step S1 and the fragment EPA obtained in step S2 to obtain a transformation mixture; then, prepare a suspension of competent E. coli GB05RedTrfA, add the transformation mixture to the suspension, and obtain a cell-DNA mixture;
[0023] S3.2, the cell-DNA mixture is placed in an electroporator for electroporation, and the electroporation conditions are: voltage 1300-1400V and pulse width 4.8-5.8ms, and the cell-DNA mixture after electroporation is recovered and cultured, and then coated or inoculated on a solid selection medium; then, after the solid selection medium is cultured at 37°C for 18-36h, a single colony is picked from the solid selection medium, and then a plasmid is extracted from the single colony to obtain a plasmid pMSBBAC1-Efad containing the modified fidaxomicin biosynthetic gene cluster. Wherein, the solid selection medium contains fragment ampicillin resistance. The process of recovery culture is: add LB liquid culture medium to the cell-DNA mixture after electroporation, and incubate it on a shaker at 37°C for 1h; the volume ratio of LB liquid culture medium to the cell-DNA mixture after electroporation is 15:1.
[0024] S4. Sequencing confirms the plasmid pMSBBAC1-Efad obtained in step S3, and the plasmid pMSBBAC1-Efad is transduced into Escherichia coli E.coilET12567 / pUB307 by biparental conjugation transfer technology to obtain Escherichia coli E.coilET12567 / pUB307 / pMSBBAC1-Efad.
[0025] S5. Treat E. coli E.coil ET12567 / pUB307 / pMSBBAC1-Efad and Streptomyces albus J1074 using E. coli-Streptomyces conjugation transfer technology to obtain Streptomyces albus Efad. The specific steps are: transfer E. coli E.coil ET12567 / pUB307 / pMSBBAC1-Efad into a heterologous host by E. coli-Streptomyces conjugation transfer technology, wherein the heterologous host is Streptomyces albus J1074, to obtain a transformant; after subculturing the transformant, inoculate it into a solid culture medium, pick a single colony from the solid culture medium, and obtain the engineered strain.
[0026] (III) Application of heterologous expression engineered strains of Fidaxomicin
[0027] The fidaxomicin heterologous expression engineered strain can be used to produce fidaxomicin or prepare drugs for resisting Clostridium difficile infection.
[0028] The method for producing fidaxomicin by using the fidaxomicin heterologous expression engineered strain specifically comprises the following steps: culturing the fidaxomicin heterologous expression engineered strain by using a fermentation medium, obtaining a fermentation product after the culturing, and separating fidaxomicin from the fermentation product.
[0029] The components and pH of the fermentation medium are as follows by mass: 20 parts of glucose, 18.4 parts of soluble starch, 5 parts of yeast powder, 17.5 parts of cottonseed cake powder, 7.28 parts of dipotassium hydrogen phosphate, 3 parts of sodium chloride and 1000 parts of water; the pH is 7.2, and the temperature is 28-32°C; or 50 parts of maltodextrin, 25 parts of corn starch, 15 parts of glucose, 15 parts of soybean cake powder, 10 parts of corn steep liquor powder, 10 parts of yeast powder, 0.5 parts of dipotassium hydrogen phosphate, 10 parts of sodium chloride, 0.5 parts of potassium dihydrogen phosphate ...2 parts of glucose, 5 parts of yeast powder, 17.5 parts of cottonseed cake powder, 7.28 parts of dipotassium hydrogen phosphate, 3 parts of sodium chloride and 1000 parts of water; Potassium, 0.5 parts of potassium dihydrogen phosphate, 3 parts of calcium carbonate, 3 parts of soybean oil, 1 part of defoaming agent and 1000 parts of water; pH is 7.2, and the temperature is 28-32°C; or, including 50 parts of white sugar, 25 parts of sorbitol, 25 parts of glycerol, 3 parts of soybean oil, 10 parts of soybean cake powder, 5 parts of yeast powder, 5 parts of gluten powder, 3 parts of calcium carbonate, 2 parts of magnesium sulfate, 2 parts of potassium chloride, 0.5 parts of potassium dihydrogen phosphate, 1 part of defoaming agent and 1000 parts of water; pH is 7.0, and the temperature is 28-32°C.
[0030] The beneficial effects of the present invention are:
[0031] 1. The present invention uses genetic engineering technology to introduce a strong promoter into the biosynthetic gene cluster of fidaxomicin to obtain a modified biosynthetic gene cluster of fidaxomicin, and directly integrates the modified biosynthetic gene cluster of fidaxomicin into the genome of the host bacteria to construct a fidaxomicin heterologous expression engineered strain. This engineered strain has the advantages of simple construction process, low construction cost, high efficiency, and low risk of gene mutation.
[0032] 2. The present invention adopts the advantageous combination of ermEp* promoter and Streptomyces albus J1074, selects the fidaxomicin biosynthetic gene cluster after the ermEp* promoter transformation, and uses Streptomyces albus J1074 as the host bacteria to construct an engineered strain. Since Streptomyces albus J1074 has a strong acceptance capacity for the fidaxomicin biosynthetic gene cluster after the ermEp* promoter transformation, the success rate of conjugation transfer is further improved and the time of conjugation transfer is shortened.
[0033] 3. The engineered strain provided by the present invention can be used to prepare fidaxomicin by fermentation. The engineered strain has a fast growth rate and high metabolic efficiency, which further shortens the fermentation cycle and improves the production efficiency of fidaxomicin.
[0034] 4. The present invention further optimizes the culture medium components of the engineered strain. The production efficiency of fidaxomicin of the engineered strain in the optimal culture medium is increased by 7.6 times compared with that of Deccan Plateau Actinomycetes YP-1, and has a wide range of industrial application value. BRIEF DESCRIPTION OF THE DRAWINGS
[0035] Figure 1 Schematic diagram of the structure of the electroporated recombinant plasmid pMSBBAC1-Efad (comprising the modified fidaxomicin biosynthetic gene cluster) in Example 1 of the present invention.
[0036] Figure 2 It is a bar chart comparing the fermentation yields of Fidaxomicin in Examples 2 to 6 of the present invention.
[0037] Figure 3 It is a bar chart comparing the fermentation yields of Fidaxomicin in Example 2, Example 7 and Comparative Example 5 of the present invention.
[0038] Figure 4 It is a bar graph comparing the bonding transfer efficiency in Example 1 of the present invention and Comparative Examples 1 to 4. DETAILED DESCRIPTION
[0039] The principle of the present invention will be further described below in conjunction with the method for constructing an engineered strain provided by the present invention.
[0040] The engineering strain provided by the present invention is a combination of ermEp* promoter and ampicillin resistance tag and a recombinant expression vector constructed by the biosynthetic gene cluster of fidaxomicin derived from Deccan Plateau Actinomycetes YP-1, and the recombinant expression vector is introduced into white Streptomyces J1074. Specifically: the present invention first obtains the biosynthetic gene cluster of fidaxomicin based on the construction and screening technology of the Streptomyces genome library, so as to facilitate the heterologous expression of the target gene cluster in a heterologous host. Then, the present invention inserts a strong promoter ermEp* before the pathway-specific regulatory factor through the Red / ET large fragment DNA in vitro recombination technology, obtains the modified biosynthetic gene cluster of fidaxomicin, and enables the expression level of the biosynthetic gene cluster of fidaxomicin after the modification in the heterologous host to be maintained at a high level. Finally, the modified biosynthetic gene cluster of fidaxomicin is introduced into white Streptomyces J1074 for heterologous expression, and obtains the engineering strain of efficient synthesis of fidaxomicin, namely, white Streptomyces (Streptomycesalbus) Efad. The engineered strain, Streptomyces albus Efad, has a shake flask fermentation yield of 50 mg / L of fidaxomicin, and a 5L fermentation tank yield of 216 mg / L, which is 7.6 times higher than the original starting strain, Deccan Plateau Actinomycetes YP-1. The present invention improves the biosynthesis efficiency of fidaxomicin by in situ enhancing the expression of regulatory genes within the cluster and optimizing the culture medium, and realizes the heterologous expression of the fidaxomicin synthesis gene cluster for the first time, which has potential industrial application value.
[0041] The present invention will be further described below with reference to the accompanying drawings and examples. The experimental methods in the following examples and comparative examples are conventional methods unless otherwise specified. The materials, reagents, etc. used in the following examples can be obtained from commercial sources unless otherwise specified. The specific embodiments of the present invention are as follows:
[0042] Example 1
[0043] This example provides an exemplary scheme for constructing an engineered strain for heterologous expression of fidaxomicin.
[0044] (I) In vitro acquisition of the fidaxomicin biosynthetic gene cluster
[0045] S1. Use mixed colony PCR method to screen with two pairs of specific primers to obtain the plasmid pMSBBAC1-fad containing the target gene cluster. Specifically:
[0046] S1.1, using the biosynthetic gene cluster of fidaxomicin as the target gene cluster, two pairs of specific primers were designed based on the sequence of the target gene cluster. In this embodiment, two pairs of specific primers fad-F1 / R1 and fadF2 / R2 were designed on the left and right boundaries according to the boundary of the fidaxomicin gene cluster. The sequences of the two pairs of specific primers fad-F1 / R1 and fadF2 / R2 are respectively:
[0047] The first specific primer pair: primer fad-F1: gcacgaacactcttcaggcc, as shown in SEQ ID NO.1; primer fad-R1: tcgtcgctgcgcacgtacag, as shown in SEQ ID NO.2;
[0048] The second specific primer pair: primer fadF2: gatgacgatctgctcgcgcg, as shown in SEQ ID NO.3; primer fadR2: gcggctgtgagaaactgccg, as shown in SEQ ID NO.4.
[0049] S1.2, use two pairs of specific primers to locate the target gene cluster from the BAC library of Deccan Plateau Actinomycetes YP-1, and adopt mixed colony PCR method to screen and obtain the Escherichia coli containing the target gene cluster. In this step: first, based on the Deccan Plateau Actinomycetes YP-1 strain, through DNA extraction, BAC vector selection (pMSBBAC1), digestion and connection, transformation, screening and purification, sequence determination and other steps, the high-quality library of Deccan Plateau Actinomycetes YP-1 is prepared. Then, adopt the screening method based on mixed colony PCR technology, according to two pairs of specific primers, the Escherichia coli monoclonal suspension of the 18th column (6-I-18) of the 6th plate is located to contain the complete target Fidaxomycin gene cluster, and the Escherichia coli monoclonal suspension containing the target gene cluster is obtained.
[0050] S1.3. Cultivate E. coli containing the target gene cluster, and extract a large plasmid from it to obtain a plasmid pMSBBAC1-fad containing the target gene cluster. The specific operation of extracting the large plasmid containing the fidaxomicin gene cluster is as follows:
[0051] a) Pour 4 mL of LB liquid culture medium into a test tube, add apramycin, and then inoculate with a monoclonal suspension of Escherichia coli containing a plasmid containing the fidaxomicin gene cluster. Place the inoculated test tube in a shaking incubator at 37°C and 250 rpm, shake and culture overnight to obtain a cultured bacterial suspension; centrifuge the cultured bacterial suspension at room temperature and 13,000 rpm for 1 min, and remove the supernatant as much as possible; add 200 μL of P1 buffer to the test tube containing the bacterial precipitate to resuspend the bacteria to obtain the first bacterial suspension;
[0052] b) Add 200 μL of P2 buffer to the first bacterial suspension obtained in step a), mix by inverting; then add 200 μL of P3 buffer, mix gently by inverting. Then, centrifuge at 15,000 rpm for 10 min at room temperature;
[0053] c) After centrifugation, transfer 500 μL of the supernatant to a new 1.5 mL EP tube, add 600 μL of pre-cooled isopropanol solution, and shake vigorously 5 to 6 times (to increase the yield of plasmid DNA); centrifuge at 4°C and 15,000 rpm for 10 minutes; after centrifugation, remove the supernatant as much as possible, add 1 mL of 75% ethanol to the precipitate to wash the precipitate, and obtain the second bacterial suspension;
[0054] d) The second bacterial suspension was centrifuged again at 4°C and 15,000 rpm for 1 minute, the ethanol was poured off, the EP tube was inverted on clean absorbent paper to remove the residual liquid, and then the EP tube was dried in a metal bath at 60°C for 10 minutes. Distilled water was added to the dried EP tube to dissolve the plasmid DNA to obtain the plasmid pMSBBAC1-fad containing the target gene cluster, and the plasmid pMSBBACl-fad was used as a plasmid template for the next Red / ET linear recombination process.
[0055] (II) In situ replacement of pathway-specific regulatory protein promoters
[0056] S2. Construct fragment EPA by PCR technology. The sequence of fragment EPA includes the ermEp* promoter fragment and the ampicillin resistance tag. The sequence of the ermEp* promoter fragment is shown in SEQ ID NO.5, and the sequence of the ampicillin resistance tag is shown in SEQ ID NO.6. This step is specifically as follows:
[0057] S2.1, using primers ermEp*-F1 and primer ermEp*R1 to amplify the ermEp* promoter fragment with pIJ8630-ermEp* as a template, and recovering the ermEp* promoter fragment. At the same time, using primers AMP-F2 and primer AMP-R2 to amplify the ampicillin resistance tag with pTA2 vector as a template, and recovering the ampicillin resistance tag.
[0058] S2.2. Use primer ermEp*-F1 and primer AMP-R2 to perform fusion PCR with the ermEp* promoter fragment and ampicillin resistance tag as templates to obtain the DNA fragment EPA.
[0059] The nucleotide sequence of fragment EPA is shown as SEQ ID NO.11; the nucleotide sequences of primer ermEp*-F1, primer ermEp*R1, primer AMP-F2, and primer AMP-R2 are shown as SEQ ID NO.7, SEQ ID NO.8, SEQ ID NO.9, and SEQ ID NO.10, respectively.
[0060] S3, electroporation transformation of the plasmid pMSBBAC1-fad containing the target gene cluster obtained in step S1, the fragment EPA obtained in step S2 and the competent E. coli GB05RedTrfA, realizing linear-loop recombination in E. coli, and obtaining the plasmid pMSBBAC1-Efad containing the modified fidaxomicin biosynthetic gene cluster. Specifically:
[0061] S3.1. Mix the plasmid pMSBBAC1-fad containing the target gene cluster obtained in step S1 and the fragment EPA obtained in step S2 to obtain a transformation mixture. Next, prepare a suspension of competent E. coli GB05 RedTrfA, add the transformation mixture to the suspension, and obtain a cell-DNA mixture. The specific process is:
[0062] S3.1.1. Transfer a single clone of E. coli GB05RedTrfA (containing pSC101-BAD-ETgA-tet plasmid) to 6 mL of LB liquid medium (add tetracycline to a final concentration of 5 μg / mL) and culture overnight at 30°C and 220 rpm in a shaking incubator for 14 h;
[0063] S3.1.2, take a 2mL sterile EP tube (with a hole in the lid), dispense 1.4mL of LB liquid medium (tetracycline resistance), add 20-40μL of bacterial solution, and culture at 30℃, 220rpm in a shaking incubator for 2h until OD 600 At about 0.4, add 35 μL of 10% L-rhamnose as an inducer and transfer to 37°C for culture until the bacterial OD reaches 600 Reach 0.8, about 40min;
[0064] S3.1.3, then centrifuge at 7500rpm for 1min, discard the supernatant; add 1mL 10% sterile glycerol to resuspend the cells, centrifuge at 7500rpm for 1min, discard the supernatant, and wash again;
[0065] S3.1.4. Add 40 μL of 10% glycerol to the washed bacteria, resuspend by pipetting, and then add 10 μL of transformation mixture (2 μL of plasmid pMSBBAC1-fad and 8 μL of fragment EPA) to obtain a cell-DNA mixture.
[0066] S3.2, the cell-DNA mixture was placed in an electroporator, and the electroporator was used to achieve transient transfer under the conditions of voltage 1350V, capacitance 10μF, resistance 600Ω and pulse width 4.8-5.8ms. Then 750μL of LB liquid culture medium was added, and after incubation on a 37°C shaker for 1h, a solid plate (containing fragment ampicillin resistance) was coated, and cultured at 37°C for about 18-36h, a single colony was picked from the solid plate, and a plasmid was extracted from the single colony to obtain a recombinant plasmid pMSBBAC1-Efad containing the modified fidaxomicin biosynthetic gene cluster. The structural schematic diagram of the plasmid pMSBBAC1-Efad is as follows: Figure 1 .
[0067] like Figure 1 As shown, in the plasmid pMSBBAC1-Efad, the oxygen methyltransferase gene fadS5 is co-transcribed with the pathway-specific regulatory gene fadR1, the strong promoter ermEp* is located upstream of fadS5 and fadR1, and the plasmid contains the φC31 site-specific integrase Integrase1, the phage attachment site Attp site and the apramycin resistance tag acc(3)IV.
[0068] (III) Conjugation transfer between Streptomyces and Escherichia coli (containing large plasmids)
[0069] S4. The plasmid pMSBBAC1-Efad obtained in step S3 was sequenced and verified, and the verified plasmid pMSBBAC1-Efad was transduced into Escherichia coli E.coil ET12567 / pUB307 by biparental conjugation transfer technology to obtain Escherichia coli E.coil ET12567 / pUB307 / pMSBBAC1-Efad.
[0070] The specific operation is as follows: the recombinant plasmid pMSBBAC1-Efad is introduced into E. coli DH10B again by electroporation to obtain donor E. coli DH10B, and the donor E. coli DH10B (C4I6-M) and E. coli ET12567 / pUB307 are cultured to OD 600nm = 0.4 to 0.6. The cells were precipitated by centrifugation at 4000 rpm for 4 min, washed twice with LB liquid medium, and finally suspended in a smaller volume of LB liquid medium to obtain E. coli ET12567 / pUB307 / pMSBBAC1-Efad.
[0071] S5. Escherichia coli ET12567 / pUB307 / pMSBBAC1-Efad and Streptomyces albus J1074 were treated by Escherichia coli-Streptomyces conjugation transfer technology to obtain Streptomyces albus Efad.
[0072] The specific operations are:
[0073] S5.1. Spore treatment. Fresh or frozen (stored at -80°C) purified spores of Streptomyces albus J1074 were washed twice in LB liquid medium, suspended in 500 μL of TES buffer (0.05M, pH=8.0), and then placed in a 50°C water bath for 10 min to germinate the spores. Then, an equal volume of 500 μL of YCCa germination medium was added, and the mixture was incubated at 37°C and 220 rpm for 2 to 3 hours to obtain a germinated spore suspension. The germinated spore suspension was precipitated by centrifugation, and the precipitate was collected and resuspended in TES buffer to obtain a spore suspension.
[0074] S5.2. Mixing and co-cultivation. 8 Add 10 E. coli cells ET12567 / pUB307 / pMSBBAC1-Efad to the spore suspension prepared in step S5.1 (no less than 10 cells per conjugation). 8 spores), wherein DH10B:ET12567(pUB307)≈1:1, the mixture is spread on an MS agar plate to obtain a junction plate. The junction plate is placed at 30°C for incubation for 12 to 16 hours, and then apramycin and nalidixic acid are spread on the surface of the junction plate, and the junction plate is cultured at 30°C for 3 to 5 days until transformants can be picked out. The first specific primer pair fad-F1 / R1 and the second specific primer pair fadF2 / R2 are also used to verify the successful introduction of the modified fidaxomycin gene cluster, and the verified transformant is named Streptomyces albus Efad, which is the engineered strain provided by the present invention.
[0075] Comparative Example 1
[0076] In this comparative example, Escherichia coli E.coil ET12567 / pUB307 / pMSBBAC1-Efad was constructed in the same manner as in Example 1, and Escherichia coli E.coil ET12567 / pUB307 / pMSBBAC1-Efad and Streptomyces natuarum M1154 were treated by conjugation transfer technology to construct an engineering strain of Streptomyces natuarum.
[0077] Comparative Example 2
[0078] In this comparative example, Escherichia coli E.coil ET12567 / pUB307 / pMSBBAC1-Efad was constructed in the same manner as in Example 1, and Escherichia coli E.coil ET12567 / pUB307 / pMSBBAC1-Efad and Streptomyces avermitilis SUKA22 were treated by conjugation transfer technology to construct an engineered strain of Streptomyces avermitilis.
[0079] Comparative Example 3
[0080] In this comparative example, Escherichia coli E.coil ET12567 / pUB307 / pMSBBAC1-Efad was constructed in the same manner as in Example 1, and Escherichia coli E.coil ET12567 / pUB307 / pMSBBAC1-Efad and Chattanooga Streptomyces L321 were treated by conjugation transfer technology. After multiple conjugation transfers, no transformants appeared, indicating that Chattanooga Streptomyces L321 had a low acceptance capacity for the modified fidaxomicin biosynthetic gene cluster.
[0081] Comparative Example 4
[0082] In this comparative example, E. coli E.coil ET12567 / pUB307 / pMSBBAC1-Efad was constructed in the same manner as in Example 1, and E. coli E.coil ET12567 / pUB307 / pMSBBAC1-Efad and Streptomyces albus ZXJ-6 were treated by E. coli-Streptomyces conjugation transfer technology. After multiple conjugation transfers, no transformants appeared. It can be seen that Streptomyces albus ZXJ-6 has a low acceptance capacity for the modified fidaxomicin biosynthetic gene cluster.
[0083] For Example 1 and Comparative Examples 1 to 4, the present invention measured the conjugation transfer efficiency of each host strain, and the results are as follows: Figure 4 As shown. It can be seen that the conjugation transfer efficiency of the Deccan Plateau Actinomycetes YP-1 as the host strain is 1, the conjugation transfer efficiency of Streptomyces albus J1074 is 256, the conjugation transfer efficiency of Streptomyces natural color M1154 is 1.6, and the conjugation transfer efficiency of Streptomyces avermitilis SUKA22 is 5.7. It can be seen that Streptomyces albus J1074 has a higher conjugation transfer efficiency.
[0084] In the following examples and comparative examples, the Streptomyces albus Efad strain constructed in Example 1 and the engineered strains constructed in Comparative Examples 1 and 2 are used to produce fidaxomicin by fermentation, and the fermentation yield of each engineered strain is described in detail.
[0085] Example 2
[0086] The white Streptomyces Efad constructed in Example 1 was cultured on MS solid medium for 7 days, and a bacterial block of about 1.5 cm×1.5 cm was scraped from the MS solid medium, and the bacterial block was inoculated into TSB seed medium, and cultured at 30°C and 220 rpm for 24 hours to obtain the mycelium of white Streptomyces Efad. Then, the mycelium of white Streptomyces Efad was inoculated into YEME fermentation medium, with an inoculation amount of 5%, and cultured in a 250 mL shake flask at 30°C for 168 hours, with 3 parallels in each group, and 0.2 mL of fermentation broth was sampled from the fermentation broth, and the yield of fidaxomicin was determined by HPLC.
[0087] The steps of determining the production of fidaxomicin by HPLC are as follows: add 0.8 mL of methanol to 0.2 mL of fermentation broth obtained by fermentation, shake thoroughly, centrifuge at 15000 rpm / min for 5 min, take the supernatant, and filter the supernatant with a 0.22 μm sterile microporous filter membrane, collect the filtrate as a sample, and detect the fidaxomicin content in the sample by HPLC.
[0088] Among them, the HPLC conditions are: chromatographic column: C18 column (Aglient, Eclipse Plus XDB, 5mm, 4.6mm*250mm); detection wavelength: 254nm; flow rate: 1.00mL / min; injection volume: 10μL; experimental mobile phase: mobile phase A is water containing 0.08% (v / v) trifluoroacetic acid, and mobile phase B is pure acetonitrile; HPLC program: 0-20min, 34%-90% B phase; 20-25min, 90% B phase; 25-28min, 90-34% B phase; 28-35min, 34% B phase.
[0089] Embodiment 3 to Embodiment 6
[0090] According to the method in Example 2, the Streptomyces albus Efad constructed in Example 1 was cultured in different actinomycete fermentation media to obtain fermentation broths, and the yield of fidaxomicin in the fermentation broths was determined. The actinomycete fermentation media used in Examples 3 to 6 were: R5A fermentation medium (Example 3), No. 1 fermentation medium (Example 4), No. 2 fermentation medium (Example 5), and No. 3 fermentation medium (Example 6).
[0091] Example 7
[0092] The Streptomyces albus Efad constructed in Example 1 was inoculated into fermentation medium No. 1 with an inoculation amount of 5%. After culturing for 168 h at 30° C. in a 5 L fermenter, 0.2 mL of the fermentation broth was taken and the yield of fidaxomicin in the fermentation broth was determined.
[0093] Comparative Example 5
[0094] The Deccan Plateau Actinomycetes YP-1 was cultured on ISP4 solid medium for 7 days, and a bacterial block of about 1.5 cm × 1.5 cm was scraped from the solid medium, and the bacterial block was inoculated into TSB seed medium, and cultured at 30°C and 220rpm for 24 hours to obtain the mycelium of the Deccan Plateau Actinomycetes YP-1. The mycelium of the Deccan Plateau Actinomycetes YP-1 was inoculated into the YEME fermentation medium with an inoculation amount of 5%, and cultured in a 250mL shake flask at a temperature of 30°C for 168 hours. Each group had 3 parallels, and samples were taken from the fermentation broth to obtain 0.2mL of the fermentation broth, and the yield of fidaxomicin was determined by HPLC.
[0095] Comparative Example 6
[0096] According to the method in Example 2, the engineered strain of Streptomyces chromogenes constructed in Comparative Example 1 was cultured in YEME fermentation medium to obtain a fermentation broth, and the yield of fidaxomicin in the fermentation broth was determined.
[0097] Comparative Example 7
[0098] According to the method in Example 2, the engineered strain of Streptomyces avermitilis constructed in Comparative Example 2 was cultured in YEME fermentation medium to obtain a fermentation broth, and the yield of fidaxomicin in the fermentation broth was determined.
[0099] The yields of Fidaxomicin in the above examples and comparative examples are as follows:
[0100] Figure 2 The bar graph shows the yield of fidaxomicin in Examples 2 to 6. The yield of fidaxomicin in Examples 2 to 6 is 50 mg / L (YEME), 57 mg / L (R5A), 86 mg / L (No. 1), 49 mg / L (No. 2), and 38 mg / L (No. 3), respectively.
[0101] Figure 3 The figure is a bar graph of the yield of fidaxomicin in Example 2, Example 7 and Comparative Example 5. The yields of fidaxomicin in Example 2, Example 7 and Comparative Example 5 are 50 mg / L (Efad), 216 mg / L (Efad-5L), and 24 mg / L (YP-1), respectively.
[0102] Comparing the yields of fidaxomicin in Examples 2 to 6, it can be seen that when Streptomyces albus Efad was cultured in fermentation medium No. 1 (Example 4), the yield of fidaxomicin was the highest, reaching 86 mg / L. Therefore, it was further confirmed that fermentation medium No. 1 was the optimal medium.
[0103] Comparing the yields of fidaxomicin in Example 2 with that in Example 7, it can be seen that after selecting the optimal culture medium and culturing in a 5L fermenter, the yield of fidaxomicin is further improved, and the yield after 168h reaches 216mg / L.
[0104] Comparing the yields of fidaxomicin in Example 2 with those in Comparative Examples 6 and 7, the yield of fidaxomicin in Comparative Example 6 was 0.33 mg / L, and the yield of fidaxomicin in Comparative Example 7 was 0.96 mg, both of which were much lower than the yield of fidaxomicin in Example 2.
[0105] Comparing the yields of fidaxomicin in Example 2 and Comparative Example 5, it can be seen that in the YEME fermentation medium, the fermentation yield of Streptomyces albus Efad is twice that of Actinomycetes spp. YP-1 in the Deccan Plateau.
[0106] Comparing the yields of fidaxomicin in Example 4 and Comparative Example 5, it can be seen that in the respective optimal culture media, the fermentation yield of Streptomyces albus Efad is 3.5 times that of Actinomycetes spp. YP-1. The above comparison further illustrates that the fermentation yield of Streptomyces albus Efad is significantly increased compared with the original starting strain.
[0107] Comparing the yields of fidaxomicin in Example 7 and Comparative Example 5, it can be seen that after selecting the optimal culture medium and culturing in a 5L fermenter, the yield of fidaxomicin increased by 7.6 times compared with the original starting strain (Comparative Example 5).
[0108] Finally, in order to further prove that the engineered strain constructed by the present invention has the advantage of high conjugation efficiency, the scheme using Deccan Plateau Actinomycetes YP-1 as the host bacteria was used as a control. If Deccan Plateau Actinomycetes YP-1 is used as the host bacteria, the growth period of the transformant is more than 10 days during the conjugation transfer process, while the engineered strain constructed by the present invention, Streptomyces albus Efad, can obtain transformants in only 4 days.
[0109] In addition, in actual production, the culture and fermentation cycle of the engineered strain, Streptomyces albus Efad, constructed by the present invention is: solid culture for about 3 days, conjugation transfer for 4 days, liquid seed culture for 1 day, and fermentation for 5 days. When Deccan Plateau Actinomycetes YP-1 is used as the host bacteria, the culture and fermentation cycle is: solid culture for about 8 days, conjugation transfer to grow transformants for 10 days or more, liquid seed culture for 2 days, and fermentation for 7 days. It can be seen that the engineering strain provided by the present invention has higher transformation efficiency and higher production capacity per unit time, thereby further shortening the cycle of culture, fermentation and genetic engineering transformation.
[0110] In summary, the present invention utilizes genetic engineering technology to introduce a strong promoter into the biosynthetic gene cluster of Fidaxomycin, obtains the modified biosynthetic gene cluster of Fidaxomycin, and finds that Streptomyces albus J1074 has a strong receptivity for the biosynthetic gene cluster of Fidaxomycin after the modification of the ermEp* promoter. The conjugation transfer efficiency of the engineering strain finally constructed is 256 times that of the original strain, and transformants can be obtained in only four days, which improves the biosynthetic efficiency of Fidaxomycin. In addition, the liquid seed culture time of the engineering strain is shortened to 1 day, the fermentation time is shortened to 5 days, and the output efficiency of Fidaxomycin in the optimal culture medium is improved by 7.6 times compared to Deccan Plateau Actinomycetes YP-1, so it has a wide range of industrial application value and industrialization prospects.
[0111] The formulas of the culture medium and reagents used in all embodiments of the present invention are as follows:
[0112] LB liquid medium: peptone 10.0 g, yeast extract 5.0 g, NaCl 10 g, agar 20.0 g, distilled water 1000 mL, pH 7.2.
[0113] MS solid culture medium: 20 g mannitol, 20 g soybean powder, 20 g agarose, 1000 mL distilled water, pH 7.3; the culture medium for conjugation transfer needs to be added with a final concentration of 10 mM MgCl2 solution after sterilization.
[0114] TSB seed medium: 20 g TSB solid powder (BD TM ), distilled water 1000mL, pH 7.2.
[0115] YEME fermentation medium: 5 g tryptone, 40 g glucose, 3 g yeast extract, 3 g malt extract, 1000 mL distilled water, pH 7.2.
[0116] R5A fermentation medium: sucrose 95 g, potassium sulfate 0.24 g, magnesium chloride 10.12 g, glucose 10 g, casamino acid 0.1 g, yeast extract 5 g, MOPS 20 g, trace element solution 2 mL, make up the volume to 1 L with water, and adjust the pH to 6.8 with NaOH solution.
[0117] Trace element solution: ZnCl2 40mg, FeCl3·6H2O 200mg, CuCl2·2H2O 10mg, MnCl2·4H2O 10mg, Na2B4O7·10H2O 10mg, (NH4)Mo7O4·4H2O 10mg, add water to make up to 1L, sterilize under high pressure and set aside.
[0118] Fermentation medium No. 1: 20 g glucose, 18.4 g soluble starch (CAS: 9005-84-9), 5 g yeast powder, 17.5 g cottonseed cake powder, 7.28 g dipotassium hydrogen phosphate, 3 g sodium chloride, 1000 mL distilled water, pH 7.2.
[0119] Fermentation medium No. 2: 50g maltodextrin, 25g corn starch, 15g glucose, 15g soybean cake powder, 10g corn syrup powder, 10g yeast powder, 0.5g dipotassium hydrogen phosphate, 0.5g potassium dihydrogen phosphate, 3g calcium carbonate, 3g soybean oil, 1g defoaming agent; dissolve the above ingredients in 1L water and adjust the pH to 7.2.
[0120] Fermentation medium No. 3: 50g white sugar, 25g sorbitol, 25g glycerol, 3g soybean oil, 10g soybean cake powder, 5g yeast powder, 5g gluten powder, 3g calcium carbonate, 2g magnesium sulfate, 2g potassium chloride, 0.5g potassium dihydrogen phosphate, 1g defoaming agent; dissolve the above ingredients in 1L water and adjust the pH to 7.0.
[0121] P1 buffer: 10 mM EDTA (pH 8.0), 50 mM Tris·Cl, 100 μg / mL RNase A, stored in a 4°C refrigerator.
[0122] P2 buffer: 200 mM NaOH, 1% SDS.
[0123] P3 buffer: 3.0 M potassium acetate, adjusted to pH 5.5, stored in a 4°C refrigerator.
[0124] TES buffer: 2-[Tris(hydroxymethyl)methylamino]-1-ethanesulfonic acid, Chinese name 2-[[Tris(hydroxymethyl)methyl]amino]ethanesulfonic acid, white crystalline powder, biological buffer.
[0125] YCCa germination medium: contains 1% yeast extract, 1% Casamino acids and 0.01M CaCl2.
[0126] The antibody amino acid sequence and nucleic acid sequence involved in the present invention are:
[0127] SEQ ID NO.1:
[0128] Name: Primer fad-F1
[0129] Sequence type: DNA (other DNA)
[0130] Organism source: synthetic construct
[0131] gcacgaacactcttcaggcc
[0132] SEQ ID NO.2:
[0133] Name: Primer fad-R1
[0134] Sequence type: DNA (other DNA)
[0135] Organism source: synthetic construct
[0136] tcgtcgctgcgcacgtacag
[0137] SEQ ID NO.3:
[0138] Name: Primer fadF2
[0139] Sequence type: DNA (other DNA)
[0140] Organism source: synthetic construct
[0141] gatgacgatctgctcgcgcg
[0142] SEQ ID NO.4:
[0143] Name: Primer fadR2
[0144] Sequence type: DNA (other DNA)
[0145] Organism source: synthetic construct
[0146] gcggctgtga gaaactgccg
[0147] SEQ ID NO.5:
[0148] Name: ermEp* promoter
[0149] Sequence type: DNA (other DNA)
[0150] Organism source: synthetic construct
[0151]
[0152] SEQ ID NO.6:
[0153] Name: Ampicillin resistance tag
[0154] Sequence type: DNA (other DNA)
[0155] Organism source: synthetic construct
[0156]
[0157] SEQ ID NO.7:
[0158] Name: Primer ermEp*-F1
[0159] Sequence type: DNA (other DNA)
[0160] Organism source: synthetic construct
[0161] gcccgccgcgtttgtcagatcggcgatcgcggccatcatatgatgtccgcctcctttgg
[0162] SEQ ID NO.8:
[0163] Name: Primer ermEp*R1
[0164] Sequence type: DNA (other DNA)
[0165] Organism source: synthetic construct
[0166] aaacaaataggggttccgcggcggtcgatcttgacggctg
[0167] SEQ ID NO.9:
[0168] Name: Primer AMP-F2
[0169] Sequence type: DNA (other DNA)
[0170] Organism source: synthetic construct
[0171] cagccgtcaagatcgaccgccgcggaacccctatttgttt
[0172] SEQ ID NO.10:
[0173] Name: Primer AMP-R2
[0174] Sequence type: DNA (other DNA)
[0175] Organism source: synthetic construct
[0176] gcgtccgatgtgtttcggggagttgagcgattcgtttaccaatgcttaatcagtgaggc
[0177] SEQ ID NO.11:
[0178] Name: Fragment EPA
[0179] Sequence type: DNA (other DNA)
[0180] Organism source: synthetic construct
[0181]
[0182] SEQ ID NO.12:
[0183] Name: The modified 74976-81800 base sequence of the biosynthetic gene cluster of Fidaxomicin
[0184] Sequence type: DNA (other DNA)
[0185] Organism source: synthetic construct
[0186]
[0187]
[0188]
Claims
1. A Fidaxomicin heterologous expression engineered strain, characterized by: The host bacteria of the engineered strain is Streptomyces albus J1074; the engineered strain expresses a modified fidaxomicin biosynthetic gene cluster, the modified fidaxomicin biosynthetic gene cluster is formed by replacing the promoter of the fidaxomicin biosynthetic gene cluster with an ermEp* promoter, the sequence of the ermEp* promoter is shown in SEQ ID NO.5, and the fidaxomicin biosynthetic gene cluster is derived from Actinoplanes deccanensis YP-1.
2. The heterologous expression engineered strain of Fidaxomycin according to claim 1, characterized in that: The modified fidaxomicin biosynthetic gene cluster comprises the fadP1 gene, the fadP1 promoter sequence, the ermEp* promoter sequence, the ampicillin resistance gene, the fadS5 gene and the fadR1 gene; The fadP1 gene is located upstream of the ermEp* promoter and the ampicillin resistance gene, the fadS5 gene is located downstream of the ermEp* promoter sequence, and the fadR1 gene is located downstream of the fadS5 gene; The fadP1 gene is located at bases 1 to 1179 of the base sequence shown in SEQ ID NO.12; the fadP1 promoter sequence is located at bases 1180 to 1599 of the base sequence shown in SEQ ID NO.12, the ampicillin resistance gene sequence is located at bases 1600 to 2460 of the base sequence shown in SEQ ID NO.12, the ermEp* promoter sequence is located at bases 2461 to 2708 of the base sequence shown in SEQ ID NO.12, the fadS5 gene is located at bases 2709 to 4019 of the base sequence shown in SEQ ID NO.12; and the fadR1 gene is located at bases 4020 to 6825 of the base sequence shown in SEQ ID NO.
12.
3. The heterologous expression engineered strain of Fidaxomycin according to claim 1, characterized in that: The engineering strain is classified and named Streptomyces a1bus Efad, and the preservation unit is the General Microbiology Center of China Microbiological Culture Collection Administration, the preservation number is CGMCCNO.30730, and the preservation date is May 22, 2024.
4. A method for constructing a heterologous expression engineered strain of Fidaxomycin according to any one of claims 1 to 3, characterized in that: The following steps are involved: S1, using the fidaxomicin biosynthetic gene cluster as the target gene cluster, and using two pairs of specific primers to screen the plasmid pMSBBAC1-fad containing the target gene cluster through a mixed colony PCR method; The two pairs of specific primers include a first specific primer pair and a second specific primer pair, wherein the first specific primer pair consists of primer fad-F1 and primer fad-R1, and the second specific primer pair consists of primer fadF2 and primer fadR2, and the nucleotide sequences of primer fad-F1, primer fad-R1, primer fadF2, and primer fadR2 are shown in SEQ ID NO.1, SEQ ID NO.2, SEQ ID NO.3, and SEQ ID NO.4, respectively; S2. constructing a fragment EPA by PCR technology, wherein the sequence of the fragment EPA includes the ermEp* promoter and an ampicillin resistance tag, and the sequence of the ampicillin resistance tag is shown in SEQ ID NO.6; S3, electroporating the mixture of the plasmid pMSBBAC1-fad containing the target gene cluster obtained in step S1, the fragment EPA obtained in step S2, and the competent E. coli GB05RedTrfA to obtain the plasmid pMSBBAC1-Efad containing the modified fidaxomicin biosynthetic gene cluster; S4, transducing the plasmid pMSBBAC1-Efad into Escherichia coli E.coilET12567 / pUB307 by biparental conjugation transfer technology to obtain Escherichia coli E.coilET12567 / pUB307 / pMSBBAC1-Efad; S5. Use E. coli-Streptomyces conjugation transfer technology to treat E. coli ET12567 / pUB307 / pMSBBAC1-Efad and Streptomyces albus J1074 to obtain Streptomyces albus Efad.
5. The method for constructing a heterologous expression engineered strain of Fidaxomicin according to claim 4, characterized in that: The step S1 is specifically as follows: S1.1, taking the fidaxomicin biosynthetic gene cluster as the target gene cluster, and designing two pairs of specific primers based on the sequence of the target gene cluster; S1.2, using two pairs of specific primers to locate the target gene cluster from the BAC library of Deccan Plateau Actinomycetes YP-1, and using the mixed colony PCR method to screen and obtain Escherichia coli containing the target gene cluster; S1.
3. Cultivate the Escherichia coli containing the target gene cluster, and extract plasmid from the Escherichia coli containing the target gene cluster to obtain the plasmid pMSBBAC1-fad containing the target gene cluster.
6. The method for constructing a heterologous expression engineered strain of Fidaxomicin according to claim 4, characterized in that: The step S2 is specifically as follows: S2.1, using primers ermEp*-F1 and primer ermEp*R1 to amplify the ermEp* promoter using pIJ8630-ermEp* as a template, and recovering the ermEp* promoter; at the same time, using primers AMP-F2 and primer AMP-R2 to amplify the ampicillin resistance tag using the pTA2 vector as a template, and recovering the ampicillin resistance tag; S2.2, using primers ermEp*-F1 and primer AMP-R2 to perform fusion PCR with the ermEp* promoter and the ampicillin resistance tag as templates to obtain fragment EPA; The nucleotide sequences of the primer ermEp*-F1, primer ermEp*R1, primer AMP-F2, and primer AMP-R2 are shown as SEQ ID NO.7, SEQ ID NO.8, SEQ ID NO.9, and SEQ ID NO.10, respectively; the nucleotide sequence of the fragment EPA is shown as SEQ ID NO.
11.
7. The method for constructing a heterologous expression engineered strain of Fidaxomicin according to claim 4, characterized in that: The step S3 is specifically as follows: S3.
1. Mix the plasmid pMSBBAC1-fad obtained in step S1 and the fragment EPA obtained in step S2 to obtain a transformation mixture; then, prepare a suspension of competent E. coli GB05RedTrfA, add the transformation mixture to the suspension, and obtain a cell-DNA mixture; S3.
2. Place the cell-DNA mixture in an electroporator for electroporation under the following conditions: voltage of 1300-1400 V and pulse width of 4.8-5.8 ms. After recovery culture of the cell-DNA mixture after electroporation, spread or inoculate it onto a solid selective culture medium. Subsequently, culture the solid selective culture medium at 37°C for 18-36 hours, pick a single colony from the solid selective culture medium, and then extract the plasmid from the single colony to obtain the plasmid pMSBBAC1-Efad containing the modified fidaxomicin biosynthetic gene cluster.
8. The method for constructing a heterologous expression engineered strain of Fidaxomycin according to claim 4, characterized in that: The step S5 specifically comprises: transferring Escherichia coli ET12567 / pUB307 / pMSBBAC1-Efad into Streptomyces albus J1074 by Escherichia coli-Streptomyces conjugation transfer technology to obtain transformants; subculturing the transformants, inoculating them into solid culture medium, and picking single colonies from the solid culture medium to obtain the engineered strain.
9. Use of the heterologous expression engineered strain of fidaxomicin as described in any one of claims 1 to 3 or the heterologous expression engineered strain of fidaxomicin constructed by the construction method as described in any one of claims 4 to 8 in producing fidaxomicin or preparing drugs against Clostridium difficile infection.
10. A method for producing Fidaxomicin, characterized in that: Cultivating the heterologous expression engineered strain of fidaxomicin according to any one of claims 1 to 3 or the heterologous expression engineered strain of fidaxomicin constructed by the construction method according to any one of claims 4 to 8 using a fermentation medium, obtaining a fermentation product after the cultivation, and separating fidaxomicin from the fermentation product; The components and pH of the fermentation medium are as follows by mass: 20 parts of glucose, 18.4 parts of soluble starch, 5 parts of yeast powder, 17.5 parts of cottonseed cake powder, 7.28 parts of dipotassium hydrogen phosphate, 3 parts of sodium chloride and 1000 parts of water; the pH is 7.2, and the temperature is 28-32°C; or 50 parts of maltodextrin, 25 parts of corn starch, 15 parts of glucose, 15 parts of soybean cake powder, 10 parts of corn steep liquor powder, 10 parts of yeast powder, 0.5 parts of dipotassium hydrogen phosphate, 10 parts of sodium chloride, 0.5 parts of potassium dihydrogen phosphate ...2 parts of glucose, 5 parts of yeast powder, 17.5 parts of cottonseed cake powder, 7.28 parts of dipotassium hydrogen phosphate, 3 parts of sodium chloride and 1000 parts of water; Potassium, 0.5 parts of potassium dihydrogen phosphate, 3 parts of calcium carbonate, 3 parts of soybean oil, 1 part of defoaming agent and 1000 parts of water; pH is 7.2, and the temperature is 28-32°C; or, including 50 parts of white sugar, 25 parts of sorbitol, 25 parts of glycerol, 3 parts of soybean oil, 10 parts of soybean cake powder, 5 parts of yeast powder, 5 parts of gluten powder, 3 parts of calcium carbonate, 2 parts of magnesium sulfate, 2 parts of potassium chloride, 0.5 parts of potassium dihydrogen phosphate, 1 part of defoaming agent and 1000 parts of water; pH is 7.0, and the temperature is 28-32°C.
Citation Information
Patent Citations
Biosynthetic gene cluster of tiacumicins and application thereof
CN102115757A
Fidaxomicin genetically engineered bacterium, construction method and application
CN108841769A
Method for efficiently synthesizing mequinomycin A in streptomyces albus
CN112410278A
Actinomycete chassis strain and application thereof
CN112430555A
Traceless fixed-point transformation method of large gene cluster and application of traceless fixed-point transformation method
CN113355339A
Cited By
Heterologous expression engineering strain of tsupobiacin as well as construction method and application of heterologous expression engineering strain of tsupobiacin
CN119193453A
